Global drugmakers call on Russian government to ease current conditions for clinical trials

20 June 2016

Leading global drugmakers operating in the Russian market have called on the country’s government to ease the current conditions for conducting clinical trials of their drugs in Russia, according to recent statements from the press-service of the Russian Ministry of Health.

According to producers, for the last five years the number of rejections for approval to conduct clinical trials of their drugs in Russia has increased by more than five times, while their number continues to grow, reports The Pharma Letter’s local correspondent.

The main reasons for the rejections are insufficient data on investigational drugs provided by producers, despite the fact that the same data fully satisfied regulators from the USA, Japan and the European Union. The situation is aggravated by the regular delays in the issuance of permissions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK